Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19669154 | 0.86 | MAPT (0.43) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7873560 | 0.86 | KDM4E (0.50) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7871735 | 0.83 | MAPT (0.42) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19308335 | 0.83 | KDM4E (0.55) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9909174 | 0.83 | TTR (0.39) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12658291 | 0.83 | KDM4E (0.48) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL70123 | 0.82 | MAPT (0.75) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1685558 | 0.82 | TTR (0.37) | ALDH1A1CYP3A4MAPK1TP53TDP1 | |
| SCHEMBL3892350 | 0.80 | MAPT (0.43) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL32665527 | 0.77 | KDM4E (0.37) | KDM4EMAPTALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| CN-1751019-A | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | KISSEI PHARMACEUTICAL (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1723418-A | Composition for forming antireflection film for lithography | NISSAN CHEMICAL IND LTD (JP) | 2006-01-18 | — | — | CN | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1593666-A1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| EP-1560070-A1 | COMPOSITION FOR FORMING ANTIREFLECTION FILM FOR LITHOGRAPHY | Nissan Chemical Industries, Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20030032779-A1 | Estrogen receptor ligands | OHMAN LARS (SE) | 2003-02-13 | — | — | US | disclosed |
| EP-0980386-A2 | ESTROGEN RECEPTOR CRYSTALS AND LIGANDS | KARO BIO AB (SE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998056812-A2 | ESTROGEN RECEPTOR CRYSTALS AND LIGANDS | KARO BIO AB (SE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | KDM4E 303/4885MAPT 259/4885ALDH1A1 852/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 1936/4885MAPT 4316/4885ALDH1A1 2706/4885 |
| US-20030032779-A1 | Estrogen receptor ligands | ESR1, ESRRB, GPER1 | KDM4E 3197/4885MAPT 4298/4885ALDH1A1 2183/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | KDM4E 1534/4885MAPT 3475/4885ALDH1A1 322/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KDM4E 4202/4885MAPT 4271/4885ALDH1A1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.